The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China.
Int J Cancer. 2018 Dec 1;143(11):2862-2870. doi: 10.1002/ijc.31844. Epub 2018 Oct 3.
To investigate tumor clonal evolution in hepatocellular carcinoma (HCC), we collected 31 tumor samples,16 peritumor samples and matched PBMCs from 11 long-term follow-up patients with HCC. Whole-exome sequencing was performed to obtain SNVs and CNVs for each sample. An average of 652.2 somatic mutations were identified in each patient and the mean percentage of nonubiquitous tumor mutations was 63.7% (range, 0.7%-100%), reflecting the variety of tumor heterogeneity. Further analysis of clonal evolution was conducted based on mutation clustering results and revealed that different clonal evolution patterns indeed existed in single and multifocal HCC while these patterns were significantly correlated to patients' clinical course. These patterns clearly demonstrated different mechanisms of tumor recurrence. During tumor clonal evolution, potential therapeutic targets also emerged and vanished dynamically. Moreover, mutation analysis revealed that the contribution of mutational signature was correlated with clonal evolution history. Target sequencing of follow-up plasma samples also confirmed that ctDNA level could dynamically reflect tumor clonal/subclonal burden. By investigating clonal evolution in HCC patients, our analysis revealed that different patterns indeed existed during HCC progression and proposed a novel strategy for identifying the origin of recurrent tumor as well as optimizing treatment selection.
为了研究肝癌(HCC)中的肿瘤克隆进化,我们收集了 11 例长期随访 HCC 患者的 31 个肿瘤样本、16 个肿瘤旁样本和配对的 PBMCs。对每个样本进行全外显子组测序以获得 SNVs 和 CNVs。每位患者平均鉴定出 652.2 个体细胞突变,非同义肿瘤突变的平均百分比为 63.7%(范围:0.7%-100%),反映了肿瘤异质性的多样性。基于突变聚类结果进一步分析克隆进化,结果表明在单发和多灶性 HCC 中确实存在不同的克隆进化模式,这些模式与患者的临床病程显著相关。这些模式清楚地显示了肿瘤复发的不同机制。在肿瘤克隆进化过程中,潜在的治疗靶点也动态地出现和消失。此外,突变分析表明突变特征的贡献与克隆进化史相关。对随访血浆样本的靶向测序也证实 ctDNA 水平可以动态反映肿瘤克隆/亚克隆负担。通过研究 HCC 患者的克隆进化,我们的分析表明 HCC 进展过程中确实存在不同的模式,并提出了一种新的策略来识别复发性肿瘤的起源以及优化治疗选择。